TO THE EDITOR Colchicine (COL) is a microtubule depolymerizing drug that has been widely used for the treatment of many inflammatory skin diseases, such as Behc¸et disease, psoriasis, palmoplantar pustulosis, Sweet's syndrome, and leukocytoclastic vasculitis (Sullivan et al., 1998; Bibas et al., 2005) . With regard to its pharmacological mechanisms of action, COL is thought to primarily inhibit various functions of polymorphonuclear neutrophils, including mitosis, adhesion, migration, and phagocytosis (Keller et al., 1984; Cronstein et al., 1995; Blocker et al., 1997; Jordan and Wilson, 2004) . We recently reported totally unexpected pharmacolo-gical activities of COL (Mizumoto et al., 2005) . Briefly, COL at relatively low concentrations triggered phenotypic maturation of murine bone marrow (BM)-derived dendritic cells (DCs) as well as their production of several cytokines and chemokines. Moreover, BM-DCs pretreated with COL exhibited enhanced capacities to activate allogeneic T cells and to present a foreign protein antigen to immunologically naive CD4 T cells. Interestingly, COL pretreatment markedly improved the ability of BM-DCs to uptake FITCconjugated dextran (DX). Upon local injection in low doses, COL promoted in situ maturation and mobilization of epidermal Langerhans cells and boosted both humoral and cellular immune responses in mice (Mizumoto et al., 2005) . These observations may appear to be rather contradictory to the conventional view that COL acts as an anti-inflammatory agent (when administered systemically at high doses). Thus, we first sought to study in vitro effects of COL on human DCs.
For this purpose, we employed human DC preparations generated from CD34 þ progenitors in the cord blood. Following 24-hour pretreatment with 3 mg/ml COL, we examined surface expression of major histocompatibility complex (MHC) class II molecules, CD83, and co-stimulatory molecules CD40, CD80, and CD86 within the CD1a þ populations. COL treatment significantly elevated the expression of all tested markers of DC maturation without affecting their viability ( Figure 1a ).
Moreover, COL triggered robust production of IL-6, IL-8, macrophage inflammatory protein-1a, macrophage inflammatory protein-3a, and regulated on activation, normal T cell expressed and secreted chemokine ( Figure 1b ). However, COL failed to induce significant production of tumor necrosis factor-a. Importantly, COL pretreatment also improved the ability of human DCs to uptake FITC-DX as observed with murine DCs. Control human DCs treated with vehicle alone showed modest FITC-DX uptake at 371C and minimal surface binding at 41C, whereas COLtreated DCs showed an augmented endocytic capacity (Figure 1c ). Quantitative analysis revealed 5-fold improvement of FITC-DX uptake after COL treatment (Figure 1d ). Heterogeneity of the FITC-DX uptake profile observed in COL-treated human DC populations did not appear to reflect their states of maturation because CD86 expression was elevated uniformly in an overwhelming majority of such populations after COL treatment (data not shown).
COL treatment of murine BM-DCs augmented their capacity to internalize not only FITC-DX, but also FITC-BSA (Figure 2a ). These observations may first appear to be contradictory to the general notion that DCs downregulate their endocytic capacity upon maturation (Sallusto et al., 1995) . Selected Toll-like receptor ligands, including lipopolysaccharides, have been reported to enhance DC endocytosis via causing rapid reorganization of actin cytoskeletal filaments (West et al., 2004) . When compared with COL in parallel, however, lipopolysaccharides induced only marginal, if any, augmentation of the uptake of FITC-DX or FITC-BSA by BM-DCs (data not shown). Our findings with COL now suggest that endocytic machinery may be regulated by the extent of microtubule polymerization in DCs. Indeed, confocal micro-scopic study revealed partial disruption of microtubule networks in COL-treated BM-DCs, whereas control DCs treated with vehicle alone showed well-developed microtubule formation ( Figure  2b ). No significant change was observed in the actin microstructures after COL treatment.
Upon incorporation of apoptotic bodies and cellular proteins derived from virally infected cells and dying tumor cells, DCs are known to present the MHC II and MHC I peptide epitopes to CD4 and CD8 T cells, respectively (Huang et al., 1994; Albert et al., 1998; Sigal et al., 1999) . The latter event, termed ''cross-presentation,'' represents an unusual antigen processing pathway in which exogenous antigens are presented in a MHC I-restricted manner to CD8 T cells (Ackerman and Cresswell, 2004) . With regard to mechanisms, cross-presentation involves the fusion of endoplasmic reticulum (ER) with early phagosomes to form specialized organelles equipped with all the components required for MHC I peptide loading, such as newly synthesized MHC I molecule, transporter associated with antigen presentation (TAP), tapasin, and calreticulin. After ER-phagosome formation, maturation of ER-phagosomes through the endocytic pathway results in acquisition of lysosomal components that help the breakdown of internalized proteins. These polypeptides then are retro-transported to the cytosol for proteasome-dependent degradation, and the resulting peptides are transported back to the phagosomes via TAP complex for MHC I loading (Ackerman and Cresswell, 2004; Heath et al., 2004; Trombetta and Mellman, 2005) . Thus, we next examined the subcellular localization of exogenous antigens endocytosed by COL-stimulated DCs using FITC-DX as a probe. FITC fluorescent signals showed almost complete overlap with the blue fluorescent signals demarcating the ER compartments within 10 minutes of incubation ( Figure 2c ). Moreover, colocalization of FITC fluorescent signals with the red fluorescent signals demarcating the lysosomal compartments became detectable 30-minutes post-internalization ( Figure 2d ). We interpret these patterns to suggest sequential intracellular transports of the internalized probe to the phagosome-ER fusion compartments and then to the lysosome, a major antigen processing pathway for cross-presentation (Trombetta and Mellman, 2005) . The above observations implied further that COL may promote crosspresentation of exogenous antigens to CD8 T cells. In fact, COL-treated BM-DCs exhibited marked (5-fold) and significant (Po0.01) improvement over the vehicle-treated control DCs in their ability to cross-present intact ovalbumin (OVA) proteins (300 mg/ml) to CD8 T cells freshly isolated from OT-I TCR transgenic mice, in which a majority of CD8 T cells recognize the OVA 257-264 peptide (SIINFEKL) presented by the MHC I molecules, H-2K b (Figure 2e ). By contract, COL treatment induced only marginal (up to 1.2-fold) improvement in their ability to present the OVA 257-264 peptide (10 mg/ml) to the same OT-I CD8 T ceils. It should be noted that the extent of T-cell growth induced by COL-treated/OVA proteinloaded DCs (i.e., up to 65,000 c.p.m.) was substantial when compared to the extent observed in our positive control in which COL-treated DCs were pulsed with excessive amounts of the OVA 257-264 peptide (i.e., up to 170,000 c.p.m.). In antigen dose-dependency experiments, COL-treated DCs were found to be much more efficient than vehicle-treated DCs in their capacity to cross-present (10-100 mg/ml) OVA proteins to OT-I T cells at all tested antigen concentrations (Figure 2f ). Once again, COL treatment induced no significant or only marginal improvement of their capacity to present the OVA 257-264 peptide even in a lower concentration range (1-3 mg/ml). Taken together, these observations demonstrate that COL enhances the in vitro ability of murine BM-DCs to cross-present a protein antigen to CD8 T cells.
To recapitulate the essence of our new observations, COL was found to promote phenotypic maturation and cytokine/chemokine production by human DCs. We also found that COL markedly augments the ability of murine BM-DCs to cross-present exogenous protein antigens to CD8 T cells. At least two key questions, however, remain to be addressed experimentally. Does COL treatment also enhance antigen cross-presentation by human DCs? Can we use COL (or COL-pretreated DCs) to promote cross-presentation of tumorassociated antigens or microbial antigens in vivo? Nevertheless, this study suggests a previously unrecognized pharmacological activity of COL, which should be taken into consideration when administering COL to patients with inflammatory skin disorders. Samples then were examined for FITC signals (mean7SD, n ¼ 3) within the CD11c þ populations. (b) After 24-hour incubation with 3 mg/ml COL or vehicle alone, BM-DCs were stained for tubulin (green) or actin (red), and then examined by confocal microscopy (Leica Microsystems, Wetzlar, Germany). Fluorescence was detected using a Â 100/1.4 numeric aperture apochromatic objective (APO). Images shown are maximum intensity projections of the x-y planes generated by MetaMorph software (Universal Imaging, Downingtown, PA) and ImageJ program (NIH, Bethesda, MD). Bar ¼ 25 mm. (c) Following 24-hour pretreatment with 3 mg/ml COL, BM-DCs were stained with ER-Tracker Blue-White DPX dye (blue) from Molecular Probes (Eugene, OR) and then incubated with FITC-DX (green). (d) The same BM-DC cultures were allowed to internalize FITC-DX first, extensively washed, and then stained for lysosome (red) with LysoTracker Red DND-99 (Molecular Probes) for an additional 30 minutes at 371C to allow complete transfer of DX to the lysosome. Colocalization of FITC-DX with ER or lysosome was examined by confocal microscopy. All two-color images were acquired with a sequential scan mode using Leica Confocal Software. Bar ¼ 25 mm. (e) Following 24-hour pretreatment with 3 mg/ml COL (open symbols) or vehicle alone (closed symbols), BM-DCs propagated from C57BL/6 mice were pulsed for 1 hour with 300 mg/ml OVA protein (left panel), 10 mg/ml OVA 257-264 peptide (circles in right panel), or PBS alone (triangles). After extensive washing, the DC samples were co-cultured at the indicated numbers with OVA-reactive CD8T cells (5 Â 10 4 cells/well) purified from OT-I transgenic mice (kindly provided by Dr James Foreman, UT Southwestern). Data shown are 3 H-thymidine uptake on day 4 (mean7SD, n ¼ 3). TO THE EDITOR Photodynamic therapy (PDT) is based on the concept that a certain photoactivatable compound, called a photosensitizer, can be excited by light of the appropriate wavelength to generate cytotoxic singlet oxygen and free radicals (Hasan et al., 2006) . Although earlier reports of PDT involved microbiological applications (Raab, 1900) , clinically PDT has been developed most extensively for oncologic and ophthalmologic applications. Recent clinical outcomes of PDT using d-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX), termed ALA-PDT, in patients with cutaneous leishmaniasis (CL) have been promising (Enk et al., 2003; Gardlo et al., 2003 Gardlo et al., , 2004 Asilian and Davami, 2006) , but far from being curative.
ALA by itself is not a photosensitizer, but is processed to PpIX in the heme biosynthetic pathway where it serves as a biological precursor of PpIX. It is known that Leishmania amazonensis parasites are deficient in seven out of eight enzymes in the heme biosynthetic pathway (Sah et al., 2002) . Although Leishmania major (L. major) have not been studied for this enzyme deficiency, as they require extracorporeal supplementation with PpIX or hemin as a growth factor in vitro (Steiger and Steiger, 1976; Chang and Chang, 1985) , it is reasonable to assume that they may also be deficient in these enzymes, and that they cannot produce PpIX from ALA. Therefore, the reported efficacy of ALA-PDT for CL is somewhat intriguing.
Encouraged by clinical reports, and with a view to increasing the efficacy of ALA-PDT for CL, we performed a series of in vitro and in vivo experiments to unravel the underlying mechanisms associated with this clinical response. In an attempt to better understand the basis of ALA-PDT for CL, we identified several key questions that are addressed here: first of all, how does ALA-PDT work for CL? At the cellular level, is ALA-PpIX produced by Leishmania or by host cells, or by both? Do Leishmania parasites take up ALA-PpIX from host cells?
We studied a series of cellular events in Leishmania parasites and in infected immortalized macrophages (J774.2) during ALA-PDT. The amount of PpIX in the stationary phase of a
